Caris Life Sciences, Inc.

Caris Life Sciences, Inc. is an artificial intelligence TechBio company that provides molecular profiling services to transform healthcare using molecular information and AI/machine learning algorithms. Its molecular intelligence product portfolio includes the MI Profile Platform, a whole exome sequencing (WES) and whole transcriptome sequencing (WTS) tissue-based molecular profiling solution; the Caris Assure Platform, a WES/WTS blood-based profiling solution; and the Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solution. The company also offers Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD, a minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. Additionally, it provides pharma R&D services, including laboratory delivery, strategic data, and research services to biopharmaceutical customers.

Caris Life Sciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol CAI. Its shares are traded in United States Dollars (USD). The company is headquartered in Irving, Texas, and operates primarily in the United States, with a global presence in molecular profiling services.

Caris Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company focuses on precision oncology, leveraging artificial intelligence and molecular profiling to develop solutions for cancer detection, therapy selection, and monitoring. Its services are used by hospitals, institutions, and patients, as well as biopharmaceutical customers for research and development.

Caris Life Sciences, Inc. is headquartered in Irving, Texas, United States. The company provides molecular profiling services both in the United States and globally. Its precision oncology solutions are offered to customers such as hospitals, institutions, and patients worldwide. The company was founded in 2008 and has since expanded its reach through a comprehensive portfolio of molecular profiling platforms and early detection solutions.

Caris Life Sciences, Inc. offers a range of molecular profiling products and services. Key products include the MI Profile Platform (tissue-based WES/WTS), Caris Assure Platform (blood-based WES/WTS), Precision Whole Genome Platform (WGS-based), Caris Detect (multi-cancer early detection), Caris WGS MRD (minimal residual disease detection), and Caris ChromoSeq (for hematological cancers). The company also provides pharma R&D services, including laboratory delivery, strategic data, and research services to biopharmaceutical customers. These offerings are designed to enable precision oncology through advanced molecular information and AI-driven insights.